Your email has been successfully added to our mailing list.

×
0.0878378378378379 0.153153153153153 0.261261261261261 0.175675675675676 0.193693693693694 0.261261261261261 0.261261261261261 0.261261261261261
Stock impact report

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC

Mateon Therapeutics (MATN)  More Company Research Source: GlobeNewswire
Last mateon therapeutics earnings: 11/19 05:25 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.mateon.com
PDF AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-ß therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against COVID-19. “These interim results suggest that ARTIVeda is a well-tolerated and effective treatment for COVID-19 that produces a faster recovery time when compared to Standard of Care alone,” said Dr. Vuong Trieu, Chairman and CEO of Mateon. ARTIVeda is Mateon’s lead Ayurvedic drug against COVID-19 in India and is being developed by Mateon in partnership with Windlas Biotech Private Limited (India). ARTI-19 India is being conducted by Windlas as part of Mateon’s global effort to deploy ARTIVeda across India, Africa, and Latin America. These interim results are based on 60 randomized patients (out of 114 randomized to date) across 3 sites in India: No adverse events were reported that required disc [Read more]
Impact snapshot Event time: MATN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
MATN alerts

from News Quantified
Opt-in for
MATN alerts

from News Quantified